Last reviewed · How we verify
Propylene Glycol 0.3%
Propylene Glycol 0.3%, marketed by Innovative Medical, is positioned in the eye irritation relief segment. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity. The primary risk is the potential increase in competition following the patent expiry.
At a glance
| Generic name | Propylene Glycol 0.3% |
|---|---|
| Sponsor | Innovative Medical |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Eye Irritation Relief
- Minor Eye Discomfort Relief
Common side effects
Key clinical trials
- Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive® (PHASE1)
- Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. (PHASE1)
- Dual-Polymer Hydroxypropyl Guar-and Hyaluronic Acid Lubricants in Rheumatoid Arthritis (PHASE4)
- Management of the Ocular Surface With Preservative-Free Lubricants in Patients With Dry Eye
- Evaluation of the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops (NA)
- Effects of Carboxymethylcellulose Artificial Tears on the Eye Microbiome (PHASE4)
- A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates (PHASE2)
- Corneal Thickness Changes in Patient Undergoing Dry Eye Managment (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Propylene Glycol 0.3% CI brief — competitive landscape report
- Propylene Glycol 0.3% updates RSS · CI watch RSS
- Innovative Medical portfolio CI